composition, use of low dose pioglitazone, method of treating alzheimer type cognitive impairment in a human individual, treating cognitive decline in a human individual, determining the increased risk of developing alzheimer cognitive impairment in a human individual human subject at a predetermined age or age range to determine whether to administer low dose pioglitazone to a human subject for the treatment of cognitive impairment of alzheimer's type, to delay the onset of alzheimer's disease in an at-risk individual. to develop alzheimer's disease, to delay the onset of mild amnesia cogniti
TAKEDA PHARMACEUTICAL COMPANY LIMITED;ZINFANDEL PHARMACEUTICALS, INC.
发明人:
ALLEN D. ROSES,RAJNEESH TANEJA
申请号：
BR112013017446
公开号：
BR112013017446A2
申请日:
2012.01.09
申请国别(地区):
BR
年份:
2017
代理人:
摘要：
composition, use of low dose pioglitazone, method of treating alzheimer type cognitive impairment in a human individual, treating cognitive decline in a human individual, determining the increased risk of developing alzheimer cognitive impairment in a human individual human subject at a predetermined age or age range to determine whether to administer low dose pioglitazone to a human subject for the treatment of cognitive impairment of alzheimer's type, to delay the onset of alzheimer's disease in an at-risk individual. to develop alzheimer's disease, to delay the onset of mild amnesia cognitive impairment in an individual at risk of developing alzheimer's disease, to delay the onset of preclinical alzheimer's disease in an individual at risk of developing alzheimer's disease, of delaying the onset of prodrome alzheimer's disease in an individual at risk of developing alzheime disease In low dose pioglitazone, low dose pioglitazone medicinal products are provided herein for use in the treatment (e.g., delayed onset) of cognitive impairment of alzheimer type. These manufacturing methods are also provided. Also provided are treatment methods for alzheimer's disease which includes administering a low dose pioglitazone drug product. Methods may include determining whether an individual is at risk for developing Alzheimer's disease based on the individual's age and the tomm40 523 tenotype.composição, uso de dose baixa de pioglitazona, método de tratar a deterioração cognitiva do tipo de alzheimer em um indivíduo humano, de tratar o declínio cognitivo em um indivíduo humano, de determinar o risco aumentado de desenvolver a deterioração cognitiva do tipo de alzheimer em um indivíduo humano em uma uma idade ou faixa de idade pré-determinadas, de determinar se administrar dose baixa de pioglitazona a um indivíduo humano para o tratamento da deterioração congnitiva do tipo de alzheimer, de retardar o início da doença de alzheimer em um indivíduo em risco de desenvolver a doen
